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Abstract
We recently reported the genetic cause of autosomal dominant chronic mucocutaneous candidiasis (AD-CMC) as a
mutation in the STAT1 gene. In the present study we show that STAT1 Arg274Trp mutations in the coiled-coil (CC) domain is
the genetic cause of AD-CMC in three families of patients. Cloning and transfection experiments demonstrate that mutated
STAT1 inhibits IL12R/IL-23R signaling, with hyperphosphorylation of STAT1 as the likely underlying molecular mechanism.
Inhibition of signaling through the receptors for IL-12 and IL-23 leads to strongly diminished Th1/Th17 responses and hence
to increased susceptibility to fungal infections. The challenge for the future is to translate this knowledge into novel
strategies for the treatment of this severe immunodeficiency.
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Introduction
Chronic mucocutaneous candidiasis (CMC) is a hereditary
primary immunodeficiency characterized by severe skin and
mucosal Candida infections, dermatophytosis and onychomycosis
[1]. CMC is a heterogeneous syndrome, the best characterized
clinical entities being the autosomal recessive autoimmune
polyendocrinopathy candidiasis ectodermal dystrophy (APECED)
syndrome and autosomal dominant CMC (AD-CMC) [2].
APECED is due to mutations in the gene autoimmune regulator
(AIRE) [3], and these explain the autoimmune phenomena,
including autoantibodies against the antifungal cytokines interleu-
kin (IL)-17A, IL-17F and IL-22 [4,5]. In contrast, the genetic
cause of AD-CMC has remained unknown until very recently. In a
study performed in 5 families with AD-CMC, we reported that the
disease is caused by mutations in the gene coding for the Signal
Transducer and Activator of Transcription (STAT)1 signaling
molecule [6]. The discovery of STAT1 mutations as cause of AD-
CMC was remarkable, as STAT1 deficiency had been previously
reported to be associated with mycobacterial and viral, but not
fungal, infections [7,8]. The presence of the AD-CMC mutations
in the coiled-coil (CC) domain of STAT1, rather than in the Src
homology 2 (SH2) or DNA-binding domains of the protein as in
patients with mycobacterial/viral infections, is believed to explain
the difference [6]. Nevertheless, the cellular and molecular
mechanisms responsible for the increased susceptibility to fungal
infections in patients with AD-CMC and STAT1 mutations
remain to be deciphered.
In the present study we assessed the presence and function of
STAT1 mutations in the index family published previously [6], and
in two additional previously unreported families with AD-CMC.
We also assessed the immune abnormalities underlying the
increased susceptibility to infections in these patients.
Results and Discussion
In the present study we report that mutations in the CC-domain
of STAT1, the genetic cause of AD-CMC, lead to hyperpho-
sphorylation of STAT1 resulting in increased responsiveness to
IFN-c and impaired IL-12 and IL-23 signaling pathways. We
strengthened our recent observation that STAT1 mutations are
responsible for AD-CMC [6] by showing the Arg274Trp mutation
in the CC-domain of STAT1 in patients from three additional
families with AD-CMC. These data further establish the role of
STAT1-mediated signaling as a crucial mechanism for mucosal
antifungal defense.
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Individual P4 from the Dutch family (#1) (Figure 1A) was
demonstrated to carry the Arg274Trp mutation in exon 10 of
STAT1 similar to his father (P3), aunt (P2) and grandfather (P1)
[6]. The same STAT1 variant (c.820C.T; p.Arg274Trp) was
detected in all three individuals from the British family #2
(Figure 1B), and all three individuals from British family #3
(Figure 1C) (Figure 1D). The discovery of STAT1 mutations as a
cause of AD-CMC was rather surprising, as mutations in the SH2
or DNA-binding domains of the protein had been previously
shown to be associated with mycobacterial and viral, but not
fungal, infections [9,10]. We therefore sought to identify the
molecular mechanism behind this difference.
Lower production of IFN-c and IL-17 in AD-CMC patients
IL-12 induced no IFN-c production in cells obtained from AD-
CMC patients (Figure 2A), and IL-1b and IL-23 induced less IL-
17 production in cells from P3 and P4 from family #1 (Figure 2B).
In contrast, production of TNF-a in response to IFN-c and LPS
was higher in PBMCs from CMC patients compared to healthy
controls (Figure 2C). With these findings we have confirmed our
observations in experiments with cells from other AD-CMC
patients, as reported previously [6].
Arg274Trp STAT1 inhibits signaling via IL-12R and IL-23R
The transcription of several IFN-c-regulated genes was
measured in CD4
+ T-cells from healthy controls transfected with
either wild-type STAT1 plasmid or mutant STAT1 plasmid. The
cells were stimulated for 24 hours with either IFN-c (1 mg/mL), or
IL-b (10 ng/mL) and IL-23 (50 ng/mL), or IL-12 (10 ng/ml) and
IL-18 (10 ng/ml). In line with the experiments performed in
primary cells isolated from AD-CMC patients, CD4
+ T-cells
transfected with the mutated STAT1 allele, but not with the wild-
type allele, exhibited decreased transcription of STAT4 after
exposure to IL-1b and IL-23 (Figure 2D), and decreased
transcription of MCP1 upon IL-12 and IL-18 stimulation
(Figure 2E). In contrast, CD4
+ T-cells transfected with the mutant
STAT1 plasmid showed increased transcription of PD-L1 upon
stimulation with IFN-c (Figure 2F). Cells that were transfected
with STAT1 plasmid exhibited highly increased expression of
STAT1 as compared to untransfected cells. Furthermore, no
difference in STAT1 mRNA expression was observed between
cells either transfected with wild-type or mutant STAT1 plasmid
(Figure S1). These data correct for the possibility that the observed
effects are due to a differential expression of the wild-type
compared to the mutant STAT1 plasmid.
Based on the results of these transfection studies, it can be
concluded that the differences in gene expression observed in AD-
CMC patients as compared to healthy controls can be fully
ascribed to the presence of the Arg274Trp mutation in STAT1.
Increased phosphorylation and activity of STAT1 in
AD-CMC patients
The consistent finding of increased responsiveness to IFN-c in
cells from patients and in cells transfected with the mutated
STAT1 suggested a gain of function of STAT1. We therefore
assessed whether the Arg274Trp mutation affects phosphorylation
of STAT1. PBMCs were incubated with various stimuli and
STAT1 phosphorylation was assessed by Western blotting.
Phosphorylation of STAT1 after IFN-c stimulation was higher
in AD-CMC patients than in healthy controls (Figure 3A). The
lower bands observed on the Western blot of phosphorylated
Figure 1. Pedigrees of three families with AD-CMC. (A) Pedigree of a Dutch family with four patients affected from 3 generations. (B) Pedigree
of a UK sample with 3 patients affected from 3 generations. (C) Pedigree of a UK sample with 3 patients affected from 2 generations. Patients with
candidiasis = closed black symbols; male patients = squares; female patients = circles.
doi:10.1371/journal.pone.0029248.g001
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phosphorylated STAT1 protein. Immunofluorescence microscopy
also demonstrated increased phosphorylation of STAT1 in IFN-c-
stimulated CD4
+ cells from AD-CMC patients, but no difference
in total STAT1 (Figure 3B). These data are supported by Begitt et
al, demonstrating that mutations in the CC domain of STAT1
result in hyperphosphorylation and prolonged entrapment of
STAT1 in the nucleus, leading to inhibited nuclear export of
Figure 2. AD-CMC cells or transfection of cells with the mutated STAT1 inhibited IL-12R- and IL-23R-induced genes, but increased
IFN-c signaling. Defective IL-12R (A) and IL-23R (B) pathways in cells isolated from AD-CMC patients. Data represent mean + SEM from 3 healthy
controls and 3 AD-CMC patients (P3 and P4 from family #1 and P3 from family 2). (C) Stimulation of the IFN-c receptor pathway results in increased
production of the proinflammatory cytokine TNFa. Data represent mean + SEM from 3 healthy controls and 3 AD-CMC patients. CD4
+ T cells from
healthy controls were transfected with wild-type or mutant STAT1 plasmid. (D) Decreased transcription of STAT4 upon stimulation with IL-1b (10 ng/
mL) and IL-23 (50 ng/mL), (E) and decreased transcription of MCP1 upon IL-12 (10 ng/mL) and IL-18 (10 ng/mL) stimulation. (F) The CD4
+ cells
transfected with mutant STAT1 plasmid showed increased transcription of PD-L1 upon stimulation with IFN-c (1 mg/mL). Data represent mean + SEM
from 6 healthy controls from 3 separate experiments.
doi:10.1371/journal.pone.0029248.g002
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PLoS ONE | www.plosone.org 3 December 2011 | Volume 6 | Issue 12 | e29248Figure 3. Increased STAT1 phosphorylation in cells of AD-CMC patients. (A) PBMC from two healthy controls and two AD-CMC patients
were stimulated for two hours with culture medium, IFN-b (500 U/mL), IFN-c (1 mg/mL), IL-23 (50 ng/mL) or IL-12 (10 ng/mL). Cells were lysed, and
total STAT1, phosphorylated STAT1 and actin were assessed by Western blot. Figure is representative of two separate experiments. (B) Increased
immunofluorescence of pSTAT1 in IFN-c-stimulated CD4
+ cells from AD-CMC patients. Figure is representative of three separate experiments. (C)
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PLoS ONE | www.plosone.org 4 December 2011 | Volume 6 | Issue 12 | e29248STAT1 [11]. Also, Lui et al. demonstrated that the Arg274Trp
mutation in STAT1 leads to increased phosphorylation of STAT1
[12].
Upon IFN-c stimulation through the IFN-c receptor in
physiological conditions, the downstream signaling molecules
JAK1, JAK2 and STAT1 are activated [13]. Upon activation,
STAT1 forms homodimers, which translocate to the nucleus, in
order to induce transcription of numerous genes, including ICAM-
1[14] and MCP-1 [15]. We measured the transcription of several
IFN-c regulated genes in AD-CMC patients and in healthy
controls, to determine whether the Arg274Trp mutation in STAT1
affects its function as a transcription factor. When PBMCs were
stimulated for two hours with IFN-c (1 mg/mL), AD-CMC
patients showed increased transcription of ICAM1 and MCP-1
compared to healthy controls (Figure 3C). The transcription of
STAT1, STAT3, IDO and PD-L1 was also increased (data not
shown), supporting a gain of function mechanism for STAT1 in
AD-CMC. Moreover, also unstimulated cells from AD-CMC
patients exhibited elevated expression of these genes compared to
cells from healthy controls.
How do these molecular mechanisms explain the defective
antifungal defense in AD-CMC patients? In the present study we
show that these patients display significant deficiencies in the
capacity to mount Th1 and Th17 responses, due to defective IL-
12R and IL-23R pathways. The contributing role of a defective
IL-12R signaling for CMC is strengthened by the observation that
23% of patients with isolated IL-12R deficiency have a mild form
of CMC [16]. However, STAT1 mutations in the CC domain
additionally lead to a defective response to the cytokines IL-1b and
IL-23. These cytokines play an important role in the development
of Th17 responses, which in turn are crucial in the host defense
against mucosal fungal infections. This notion is derived from the
observation that APECED patients develop neutralizing anti-IL-
17 and anti-IL-22 antibodies during the course of the disease [4],
and that hyper-IgE syndrome patients, who suffer from chronic
onychomycosis and oropharyngeal candidiasis, display defective
Th17 responses due to STAT3 defects [17]. In line with this, we
and others have also reported chronic fungal infections in patients
with defects in the dectin-1/CARD9 pathway, leading to defective
Th17 responses [18,19]. We have also previously reported
decreased IL-17 production and Th-17 cell proliferation in
patients with AD-CMC [20]. Defective Th17 responses, in turn,
are accompanied by decreased production of IL-17 and IL-22
which translates into decreased production of antifungal beta-
defensins as well as impaired influx of neutrophils [21,22].
Therefore, the combined deficiency in IL-12R signaling and
impaired Th17 responses are likely to explain the susceptibility to
fungal infections in patients with AD-CMC.
In conclusion, we strengthen the very recent observations that
STAT1 mutations in the CC-domain are the genetic cause of AD-
CMC. Moreover, we have now deciphered the cellular and
molecular mechanisms leading to this clinical phenotype:
hyperphosphorylation of STAT1, resulting in hyper-responsive-
ness to IFN-c stimulation, but defective IL-12R and IL-23R
pathways. In the end, these defects result in markedly diminished
Th1/Th17 immunity leading to increased susceptibility to fungal
infections. Future studies are warranted to investigate the disease
mechanisms in more detail, especially to elucidate the extent of
which STAT1-STAT3 and STAT1-STAT4 heterodimers are
formed in AD-CMC patients upon stimulation with either IL-12
or IL-23. Furthermore, the challenge for the future will be to assess
the proportion of patients with AD-CMC, but also sporadic CMC,
that harbor STAT1 mutations, but especially to translate this
knowledge into novel strategies for the treatment of this severe
immunodeficiency.
Materials and Methods
Family #1
The clinical characteristics and pedigree of a Dutch Caucasian
non-consanguinous family are represented in Figure 1A and in
Table S1. The patients of the first two generations have been
previously presented [6]. Since then, the son of one of the patients
from the second generation was also diagnosed with the disease.
The patients have severe chronic oropharyngeal candidiasis and
dermatophytosis of the feet.
Family #2
The clinical characteristics and pedigree of a non-consangui-
nous British Caucasian family are presented in Figure 1B and in
Table S1. Three generations are affected with severe persistent
candidiasis of the oropharynx, nails and skin (perineum in the
child), all have iron-deficiency anemia. The grandmother and
daughter have hypothyroidism while the boy has thyroid
(peroxidise) autoantibodies but has still not developed clinical
hypothyroidism.
Family #3
The clinical characteristics and pedigree of a non-consangui-
nous British Caucasian family are presented in Figure 1C and
Table S1. The mother, her son and daughter all suffer with oral
candidiasis and hypothyroidism. The children unusually also suffer
with mouth ulcers and herpetic whitlow.
Ethics approval
The study was approved by the Ethics Committee of Radboud
University Nijmegen Medical Centre, and the Newcastle and
North Tyneside Local Research Ethics Committee. Informed
consent was obtained from all family members and healthy
controls.
Sequencing of STAT1 and AIRE mutations
To assess for the presence of STAT1 mutations in the patients,
conventional PCR and Sanger sequencing were performed. All
coding exons of the CC-domain of STAT1, including exon 10,
were amplified and analyzed. AIRE mutations were excluded by
sequencing the gene as previously described [13].
Cell isolation and stimulation
PBMCs were isolated by density gradient centrifugation of PBS-
diluted blood (1:1) over Ficoll-Paque, as previously described [6].
T cells were positively selected using CD4 microbeads (130-045-
101, Miltenyi Biotec, Utrecht, the Netherlands). Cells (5610
6/ml)
were stimulated in 96-well plates (Greiner, Nuremberg, Germany),
with combinations of IFN-c (1 mg/mL) (Boehringer Ingelheim,
Alkmaar, the Netherlands) and LPS (1 ng/ml), IL-1b (10 ng/ml)
and IL-23 (10 ng/mL), or IL-12 (1 ng/ml) and IL-18 (10 ng/ml).
After 24 or 48 hours (without serum) or 5 days of incubation (in
the presence of 10% serum), cytokine concentrations were
PBMCs from three controls and two AD-CMC patients were stimulated with culture medium, IFN-b, or IFN-c for two hours. The transcription of ICAM1
and MCP-1 was measured using RT-PCR. Bars represent means + SEM.
doi:10.1371/journal.pone.0029248.g003
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Western blotting
For immunoblotting, 10610
6 cells were lysed in 100 ml lysis
buffer (50 mM Tris, 1 mM EDTA, 150 mM NaCL, 1% ND40,
5 mM NaF, 0.05% Sodium Deoxycholate, PhosSTOP and
cOmplete proteinase inhibitor cocktail (Roche, Almere, the
Netherlands)). The homogenate was frozen, thawed then centri-
fuged at 4 uC for 10 min at 14,000 rpm, and the supernatant was
taken for Western blotting. Equal amounts of protein were
subjected to SDS-PAGE using 10% and 15% polyacrylamide gels
at a constant voltage of 100V. After SDS-PAGE, proteins were
transferred to nitrocellulose membrane (0.2 mm). The membrane
was blocked with 5% (w/v) milk powder in PBS for 1 hour at
room temperature followed by incubation overnight at 4uC with a
STAT1 or pSTAT1 (Tyr701) antibody (9172 and 9167 respec-
tively, Cell Signaling, Leiden, the Netherlands) in 5% BSA/TBS/
T (5% bovine serum albumin/Tris-buffered saline/Tween 20).
After overnight incubation the blots were washed three times with
TBS/T and incubated with HRP-conjugated goat anti-rabbit
antibody at a dilution of 1:10,000 in 5% (w/v) milk powder in PBS
for 1 hour at room temperature. After washing the blots three
times with TBS/T, the blots where developed with ECL according
to manufacturer’s instructions (GE Healthcare, Diegem, Belgium).
STAT1 Immunofluorescence
CD4
+ cells were stimulated for 10 minutes with IFN-c on cover
slides. Subsequently, the cells were fixed with 10% PFA, and
stained with a-pSTAT1 (Tyr701) or a-STAT1 and goat anti-
rabbit Alexa 488 according to manufacturer instructions. The
coverslides were mounted using Vectashield containing DAPI.
STAT1 cloning and transfection experiments
The Arg274Trp mutation was introduced into a plasmid
containing the human STAT1a gene (pUNO-hSTAT1a, Invivogen,
Toulouse, France), using the QuickChange
TM Site-Directed Muta-
genesis Kit (200518, Stratagene, Eindhoven, the Netherlands). The
following primers were used for the PCR reaction: 59-G A G - A G T -
CTG-CAG-CAA-GTT-TGG-CAG-CAG-CTT-AAA-AAG-39 (for-
ward) and 59- CTT-TTT-AAG-CTG-CTG-CCA-AAC-TTG-
CTG-CAG-ACT-CTC-39 (reverse). Human CD4
+ cells were
transfected using HIPerfect reagent (Qiagen, Venlo, the Nether-
lands), according to manufacturer instructions.
Quantitative PCR of IL-12R/IL-23R/IFN-c-responsive genes
One million freshly isolated PBMCs or (transfected) CD4
+ cells
were stimulated with IFN-c, IL-b and IL-23 or IL-12 and IL-18.
After two hours, total RNA was extracted in 400 mL TRIzol
reagent (Invitrogen). Isolated RNA was reverse transcribed into
complementary DNA using oligo(dT) primers and MMLV reverse
transcriptase. PCR was performed using a 7300 realtime PCR
system (Applied Biosystems, Lennik, Belgium). Primer sequences
are presented in Supplemental Information. PCR conditions were
as follows: two minutes at 50uC and 10 minutes at 95uC, followed
by 40 cycles of PCR reaction at 95uC for 15 seconds, and 60uC for
one minute. Primer sequences used for RT-PCR assessment were:
STAT4: 59-ACA-ATG-AAA-CCA-TGG-CAA-CGA-39 (forward)
and 59-TGA-AAT-TTT-CCC-TGA-AGG-ACC-TTC-39 (re-
verse); ICAM: 59-TTG-AAC-CCC-ACA-GTC-ACC-TAT-39
(forward) and 59-CCT-CTG-GCT-TCG-TCA-GAA-TC-39 (re-
verse); MCP-1: 59-CCA-GTC-ACC-TGC-TGT-TAT-AAC-39
(forward) and 59-TGG-AAT-CCT-GAA-CCC-ACT-TCT-39 (re-
verse); PD-L1: 59-GCT-GAA-CGC-ATT-TAC-TGT-CAC-G-39
(forward) and 59-AGT-GCA-GCC-AGG-TCT-AAT-TGT-39 (re-
verse). B2M was used as a reference housekeeping gene, for which
the primers were: 59- ATG-AGT-ATG-CCT-GCC-GTG-TG-39
(forward) and 59- CCA-AAT-GCG-GCA-TCT-TCA-AAC-39
(reverse).
Supporting Information
Figure S1 STAT1 expression in transfected CD4
+ T-
cells. STAT1 mRNA expression in CD4
+ T cells untransfected or
transfected with wild-type or mutant STAT1 plasmid. Cells were
left unstimulated or stimulated with IFN-c for 1 hour.
(DOC)
Table S1 Clinical characteristics of 8 patients with AD-
CMC from 3 families.
(DOC)
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